EMA accepts Sanofi’s advertising software for avalglucosidase for Pompe illness (NASDAQ:SNY)

0
60

The European Medicines Company (EMA) has accepted for evaluation Sanofi’s (NASDAQ:SNY) advertising authorization software for avalglucosidase alfa, for long-term enzyme substitute remedy for the remedy of sufferers with Pompe illness (acid α-glucosidase deficiency).

Pompe illness is a uncommon, degenerative muscle dysfunction that may impression a person’s skill to maneuver and breathe.

The Medicines and Healthcare Merchandise Regulatory Company within the UK has granted Promising Modern Drugs designation for avalglucosidase alfa.

The FDA has additionally granted Breakthrough Remedy and Quick Observe designations to avalglucosidase alfa.

LEAVE A REPLY

Please enter your comment!
Please enter your name here